IN2014MN01879A - - Google Patents
Info
- Publication number
- IN2014MN01879A IN2014MN01879A IN1879MUN2014A IN2014MN01879A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A IN 1879MUN2014 A IN1879MUN2014 A IN 1879MUN2014A IN 2014MN01879 A IN2014MN01879 A IN 2014MN01879A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- antibody chains
- derivatives
- chimaeric
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/433,084 US9445581B2 (en) | 2012-03-28 | 2012-03-28 | Animal models and therapeutic molecules |
US13/434,361 US9253965B2 (en) | 2012-03-28 | 2012-03-29 | Animal models and therapeutic molecules |
PCT/GB2013/050682 WO2013144566A2 (en) | 2012-03-28 | 2013-03-18 | Animal models and therapeutic molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN01879A true IN2014MN01879A (ko) | 2015-07-03 |
Family
ID=47913490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1879MUN2014 IN2014MN01879A (ko) | 2012-03-28 | 2013-03-18 |
Country Status (12)
Country | Link |
---|---|
US (7) | US9253965B2 (ko) |
EP (3) | EP2785845A2 (ko) |
JP (4) | JP6336435B2 (ko) |
CN (1) | CN104334732B (ko) |
AU (1) | AU2013239501B2 (ko) |
CA (1) | CA2867530A1 (ko) |
DK (1) | DK2831244T3 (ko) |
HK (1) | HK1200872A1 (ko) |
IN (1) | IN2014MN01879A (ko) |
NZ (1) | NZ629202A (ko) |
SG (1) | SG11201405058WA (ko) |
WO (2) | WO2013061098A2 (ko) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG174053A1 (en) | 2006-09-01 | 2011-09-29 | Therapeutic Human Polyclonals Inc | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
EP2597945B1 (en) | 2010-07-26 | 2020-07-22 | Trianni, Inc. | Transgenic animals and methods of use |
ES2612459T3 (es) | 2010-08-02 | 2017-05-17 | Regeneron Pharmaceuticals, Inc. | Ratones que producen proteínas de unión que comprenden dominios VL |
SG10201913160QA (en) | 2011-02-25 | 2020-03-30 | Regeneron Pharma | Adam6 mice |
NZ781020A (en) | 2011-08-05 | 2023-01-27 | Regeneron Pharma | Humanized universal light chain mice |
CN106995822B (zh) | 2011-09-19 | 2021-06-29 | 科马布有限公司 | 定制供人类使用的抗体、可变结构域和链 |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
KR102186822B1 (ko) | 2011-12-20 | 2020-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
RS62121B1 (sr) | 2012-06-12 | 2021-08-31 | Regeneron Pharma | Humanizovane nehumane životinje sa ograničenim lokusima imunoglobulinskog teškog lanca |
BR112015019350A2 (pt) | 2013-02-20 | 2017-08-22 | Regeneron Pharma | Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
NL2013554B1 (en) * | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
SG11201607203XA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
SG11201607015VA (en) | 2014-03-21 | 2016-09-29 | Regeneron Pharma | V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS |
BR112016022841B1 (pt) | 2014-04-03 | 2023-09-26 | Igm Biosciences, Inc | Anticorpo igm, iga, igg/igm ou igg/iga compreendendo uma cadeia j modificada |
BR112017018941B8 (pt) | 2015-03-04 | 2023-01-10 | Igm Biosciences Inc | Molécula de ligação a cd20, seu uso, composição e método in vitro para direcionar a morte mediada por complemento de uma célula que expressa cd20 |
AU2016232715A1 (en) | 2015-03-19 | 2017-09-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
CA2999284C (en) | 2015-09-30 | 2023-06-13 | Igm Biosciences A/S | Binding molecules with modified j-chain |
CN108463472A (zh) | 2015-09-30 | 2018-08-28 | Igm生物科学有限公司 | 具有修饰的j-链的结合分子 |
WO2017095939A1 (en) | 2015-12-03 | 2017-06-08 | Trianni, Inc. | Enhanced immunoglobulin diversity |
US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
IL260743B2 (en) | 2016-02-04 | 2024-03-01 | Trianni Inc | Advanced production of antibodies |
GB2550114A (en) | 2016-05-03 | 2017-11-15 | Kymab Ltd | Methods, regimens, combinations & antagonists |
BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
SG11201903344XA (en) * | 2016-11-04 | 2019-05-30 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain locus |
WO2018144097A1 (en) * | 2016-11-04 | 2018-08-09 | Akeagen Llc | Genetically modified non-human animals and methods for producing heavy chain-only antibodies |
WO2018102612A1 (en) | 2016-12-02 | 2018-06-07 | Juno Therapeutics, Inc. | Engineered b cells and related compositions and methods |
EP3574017A1 (en) | 2017-01-27 | 2019-12-04 | Kymab Limited | Anti-opg antibodies |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
GB201710984D0 (en) | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
WO2019017438A1 (ja) * | 2017-07-21 | 2019-01-24 | 株式会社Idファーマ | 標的配列を改変するためのポリヌクレオチドおよびその使用 |
WO2019037099A1 (en) * | 2017-08-25 | 2019-02-28 | Wenning Qin | LARGE SCALE MODIFICATION OF GENOME EUCARYOTE |
CA3084049A1 (en) * | 2017-12-05 | 2019-06-13 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
CN108486126A (zh) * | 2018-03-27 | 2018-09-04 | 重庆金迈博生物科技有限公司 | 一种核酸分子及其在人源化抗体中的应用 |
GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
JP2022521358A (ja) * | 2019-02-18 | 2022-04-06 | バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド | ヒト化免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物 |
SG11202110610VA (en) | 2019-04-09 | 2021-10-28 | Abcuro Inc | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
JP2022538886A (ja) * | 2019-07-01 | 2022-09-06 | トリアニ・インコーポレイテッド | トランスジェニック哺乳動物およびその使用法 |
BR112022010424A2 (pt) | 2019-11-29 | 2022-08-23 | Kymab Ltd | Tratamento para sobrecarga de ferro fisiológica |
CN115988960A (zh) | 2020-06-25 | 2023-04-18 | 株式会社湖美宝 | 杂合转基因动物 |
WO2022026775A1 (en) * | 2020-07-30 | 2022-02-03 | Prellis Biologics, Inc | Compositions and methods for targeting coronavirus |
KR20230066386A (ko) | 2020-09-11 | 2023-05-15 | 리제너론 파마슈티칼스 인코포레이티드 | 항원 특이적 항체의 확인 및 제조 |
CN116848254A (zh) | 2020-12-16 | 2023-10-03 | 瑞泽恩制药公司 | 表达人源化Fcα受体的小鼠 |
EP4377346A1 (en) | 2021-07-26 | 2024-06-05 | Abcuro, Inc. | Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
US4720449A (en) | 1985-06-03 | 1988-01-19 | Polaroid Corporation | Thermal imaging method |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
DK0463151T3 (da) | 1990-01-12 | 1996-07-01 | Cell Genesys Inc | Frembringelse af xenogene antistoffer |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) * | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
AU2515992A (en) | 1991-08-20 | 1993-03-16 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
US5859307A (en) | 1992-02-04 | 1999-01-12 | Massachusetts Institute Of Technology | Mutant RAG-1 deficient animals having no mature B and T lymphocytes |
AU675661B2 (en) | 1992-07-24 | 1997-02-13 | Abgenix, Inc. | Generation of xenogeneic antibodies |
DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
JP4242447B2 (ja) | 1993-01-22 | 2009-03-25 | イミュネックス・コーポレーション | Cd40リガンド遺伝子の突然変異の検出および治療 |
EP0754225A4 (en) | 1993-04-26 | 2001-01-31 | Genpharm Int | HETEROLOGIC ANTIBODY-PRODUCING TRANSGENIC NON-HUMAN ANIMALS |
DE4331162A1 (de) | 1993-09-14 | 1995-03-16 | Bayer Ag | Verfahren zur Herstellung von Cyaninfarbstoffen |
US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
WO1997049804A1 (en) | 1996-06-26 | 1997-12-31 | Baylor College Of Medicine | Chromosomal rearrangement by insertion of two recombination substrates |
DE69738166T2 (de) | 1996-06-27 | 2008-06-19 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Antikörpermoleküle, die spezifisch mit dem aktiven Zentrum oder dem aktiven Spalt eines Zielmoleküls interagieren |
ES2301183T3 (es) * | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
DE69839742D1 (de) | 1997-11-18 | 2008-08-28 | Pioneer Hi Bred Int | Zusammensetzungen und Verfahren für die genetische Modifizierung von Pflanzen |
WO1999029837A2 (en) | 1997-12-05 | 1999-06-17 | Europäisches Laboratorium für Molekularbiologie (EMBL) | Novel dna cloning method relying on the e. coli rece/rect recombination system |
EP0939120A1 (en) | 1998-02-27 | 1999-09-01 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Method for marker-free repetitive DNA expression cassette exchange in the genome of cells or parts of cells |
GB9823930D0 (en) * | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US6355412B1 (en) | 1999-07-09 | 2002-03-12 | The European Molecular Biology Laboratory | Methods and compositions for directed cloning and subcloning using homologous recombination |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
CA2307503A1 (en) | 2000-05-02 | 2001-11-02 | Carlos F. Barbas Iii | Peptides for use as a vaccine or treatment for hiv infection |
BR0112633A (pt) | 2000-07-21 | 2003-09-16 | Us Agriculture | Método para substituir, translocar e empilhar dna em genomas eucarióticos |
US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2001297523B2 (en) | 2000-11-17 | 2007-01-18 | Sab, Llc | Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
JP2005505236A (ja) | 2000-12-19 | 2005-02-24 | アルトー バイオサイエンス コーポレイション | ヒト化免疫系を含むトランスジェニック動物 |
EE05724B1 (et) | 2001-01-05 | 2014-10-15 | Pfizer Inc. | Antikehad insuliinitaolise kasvufaktori I retseptorile |
FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
ES2645698T3 (es) * | 2001-11-30 | 2017-12-07 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
WO2003061363A2 (en) | 2002-01-17 | 2003-07-31 | Albert Einstein College Of Medicine Of Yeshiva University | Mutations caused by activation-induced cytidine deaminase |
US8877901B2 (en) | 2002-12-13 | 2014-11-04 | Immunomedics, Inc. | Camptothecin-binding moiety conjugates |
EP1539946A4 (en) | 2002-09-09 | 2006-03-15 | California Inst Of Techn | METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE |
DE10251918A1 (de) | 2002-11-08 | 2004-05-19 | Horn, Carsten, Dipl.-Biochem. Dr. | Systeme zur Erzeugung stabiler genomischer Transgen-Insertionen |
US7700356B2 (en) | 2002-11-08 | 2010-04-20 | The United States Of America As Represented By The Secretary Of Agriculture | System for gene targeting and producing stable genomic transgene insertions |
AR042145A1 (es) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | Produccion de inmunoglobulinas en plantas con una fucocilacion reducida |
GB2398784B (en) | 2003-02-26 | 2005-07-27 | Babraham Inst | Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
WO2005001087A2 (en) | 2003-06-11 | 2005-01-06 | Regeneron Pharmaceuticals, Inc. | Methods of modifying genes in eukaryotic cells |
GB2403475B (en) | 2003-07-01 | 2008-02-06 | Oxitec Ltd | Stable integrands |
JP2005042792A (ja) | 2003-07-28 | 2005-02-17 | Nsk Ltd | ローラクラッチ及びローラクラッチ内蔵型プーリ装置 |
US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
WO2005019463A1 (en) | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
US7604994B2 (en) | 2003-09-03 | 2009-10-20 | Morphotek, Inc. | Genetically altered antibody-producing cell lines with improved antibody characteristics |
CA2445602C (en) | 2003-10-20 | 2014-01-14 | Campusgen Gmbh | Nucleotide sequence for creatinine deiminase and method of use |
HUE025328T2 (en) | 2003-12-10 | 2016-03-29 | Squibb & Sons Llc | IP-10 antibodies and their use |
JP2008507257A (ja) | 2004-03-19 | 2008-03-13 | アムゲン・インコーポレーテッド | V遺伝子の操作を介したヒト抗ヒト抗体の危険性の低減 |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
JP2008512987A (ja) | 2004-07-22 | 2008-05-01 | エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム | 結合分子 |
FR2875239B1 (fr) | 2004-09-10 | 2007-07-20 | Inst Necker Ass Loi De 1901 | Procede pour l'acceleration des mutations somatiques et son application en proteomique |
WO2006044492A2 (en) | 2004-10-14 | 2006-04-27 | Ingenious Targeting Laboratory, Inc. | Methods for generating rat embryo-derived cell lines and genetic modification of rat genome |
CA2583750C (en) | 2004-10-19 | 2015-11-24 | Regeneron Pharmaceuticals, Inc. | Methods for generating a rodent having a genetic modification |
WO2006055704A2 (en) | 2004-11-17 | 2006-05-26 | Curagen Corporation | Antibodies directed to ten-m proteins and uses thereof |
US7973140B2 (en) | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
WO2006122442A1 (en) | 2005-05-14 | 2006-11-23 | Fudan University | Piggybac as a tool for genetic manipulation and analysis in vertebrates |
EP1780272A1 (en) | 2005-10-27 | 2007-05-02 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method for enhancing somatic hypermutation, gene conversion and class switch recombination |
GB0601513D0 (en) | 2006-01-25 | 2006-03-08 | Univ Erasmus Medical Ct | Binding molecules 3 |
KR101481843B1 (ko) | 2006-01-25 | 2015-01-12 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 형질전환 동물 내에서의 중쇄만의 항체의 생성 |
US7462759B2 (en) | 2006-02-03 | 2008-12-09 | Pioneer Hi-Bred International, Inc. | Brittle stalk 2 gene family and related methods and uses |
JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
US7582298B2 (en) | 2006-06-02 | 2009-09-01 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human IL-6 receptor |
WO2008094178A2 (en) | 2006-06-27 | 2008-08-07 | Vaxdesign Corporation | Models for vaccine assessment |
EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
EP2061812A4 (en) | 2006-08-22 | 2010-06-09 | G2 Inflammation Pty Ltd | METHOD FOR THE PRODUCTION OF ANTIBODIES |
HUE054090T2 (hu) | 2006-10-02 | 2021-08-30 | Regeneron Pharma | A humán IL-4 receptorral szemben nagy affinitást mutató humán antitestek |
WO2008070367A2 (en) | 2006-11-01 | 2008-06-12 | Facet Biotech Corporation | Mammalian cell-based immunoglobulin display libraries |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
GB0700194D0 (en) | 2007-01-05 | 2007-02-14 | Univ Edinburgh | Humanisation of animals |
WO2008103475A1 (en) | 2007-02-20 | 2008-08-28 | Anaptysbio, Inc. | Somatic hypermutation systems |
BRPI0809435A2 (pt) | 2007-03-27 | 2014-09-09 | Sea Lane Biotechnologies Llc | Constructos e bibliotecas que compreendem sequências de cadeia leve substituida de anticorpos |
GB0706628D0 (en) | 2007-04-04 | 2007-05-16 | Univ Erasmus | Germ-line manipulation 1 |
EP3382022A1 (en) | 2007-06-01 | 2018-10-03 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
ES2527297T3 (es) | 2007-07-31 | 2015-01-22 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos para CD20 humano y método para utilizar los mismos |
JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル.エル.シー. | Hco32およびhco27、ならびに関連実施例 |
CN101827609B (zh) | 2007-08-10 | 2014-03-12 | 里珍纳龙药品有限公司 | 抗人神经生长因子的高亲和力人抗体 |
JP2009122383A (ja) * | 2007-11-14 | 2009-06-04 | Canon Inc | 揺動体装置の製造方法、該製造方法により製造された揺動体装置によって構成される光偏向器及び光学機器 |
EP2245155A4 (en) | 2007-12-10 | 2011-05-25 | Aliva Biopharmaceuticals Inc | METHODS FOR SEQUENTIALLY REPLACING A TARGETED AREA BY HOMOLOGOUS RECOMBINATION |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
BRPI0906711A2 (pt) | 2008-01-25 | 2015-06-30 | Cabot Corp | Médoto para preparação de pigmento coloridos modificados |
KR101409375B1 (ko) | 2008-01-31 | 2014-06-18 | 삼성전자주식회사 | 반도체 메모리장치의 블록 디코딩 회로 |
CA2718517A1 (en) | 2008-03-26 | 2009-10-01 | Iti Scotland Limited | Efficient insertion of dna into embryonic stem cells |
EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
KR20110020860A (ko) | 2008-05-23 | 2011-03-03 | 알리바 바이오파마수티컬스, 아이엔씨. | 유전자 삽입동물에서 단일 vl 도메인 항체를 생산하는 방법 |
PT2147594E (pt) | 2008-06-27 | 2014-02-17 | Merus B V | Mamíferos não humanos que produzem anticorpos |
EP3889265A1 (en) | 2008-09-30 | 2021-10-06 | Ablexis, LLC | Transgenic mice for the production of chimeric antibodies |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
CN112626117A (zh) | 2008-12-18 | 2021-04-09 | 伊拉兹马斯大学鹿特丹医学中心 | 表达人源化抗体的非人转基因动物及其用途 |
US9085795B2 (en) | 2009-02-04 | 2015-07-21 | Molecular Innovations, Inc. | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies |
CA2753287A1 (en) | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
EP2414507B1 (en) | 2009-04-03 | 2014-07-02 | Medical Research Council | Mutants of activation-induced cytidine deaminase (aid) and methods of use |
TWI560271B (en) | 2009-06-26 | 2016-12-01 | Sealane Biotechnologies Llc | Expression of surrogate light chains |
EP2564695B1 (en) | 2009-07-08 | 2015-04-15 | Kymab Limited | Animal models and therapeutic molecules |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
CA2768207C (en) | 2009-07-15 | 2019-12-03 | Aimm Therapeutics B.V. | Means and methods for producing high affinity antibodies |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
WO2011019844A1 (en) | 2009-08-13 | 2011-02-17 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal cdrs |
EP2496706A4 (en) | 2009-11-05 | 2013-07-17 | Anaptysbio Inc | PROCESS FOR PREPARING IMPROVED ANTIGEN BINDING OF THE CHAIN FORMING AND OPTIONAL SOMATIC HYPERMUTATION |
CN102741404B (zh) | 2009-11-17 | 2017-03-08 | Sab有限责任公司 | 人类人工染色体载体 |
US20120269830A1 (en) | 2009-12-07 | 2012-10-25 | Lawrence Horowitz | Conjugates with improved pharmacokinetic properties |
HUE030208T2 (en) | 2009-12-10 | 2017-04-28 | Regeneron Pharma | Heavy-chain antibody-producing mice |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
EP2501817B2 (en) | 2010-02-08 | 2021-04-21 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
EP3156062A1 (en) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Novel dna-binding proteins and uses thereof |
CN103228130B (zh) | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
CN103068993B (zh) | 2010-06-22 | 2016-01-06 | 瑞泽恩制药公司 | 杂交轻链小鼠 |
ES2612459T3 (es) | 2010-08-02 | 2017-05-17 | Regeneron Pharmaceuticals, Inc. | Ratones que producen proteínas de unión que comprenden dominios VL |
CN103261220B (zh) | 2010-08-16 | 2016-06-15 | 诺夫免疫股份有限公司 | 用于生成多特异性和多价抗体的方法 |
JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
AR084456A1 (es) | 2010-12-22 | 2013-05-15 | Genentech Inc | Anticuerpo anti-pcsk9 y metodos de uso |
SG10201913160QA (en) | 2011-02-25 | 2020-03-30 | Regeneron Pharma | Adam6 mice |
NZ781020A (en) | 2011-08-05 | 2023-01-27 | Regeneron Pharma | Humanized universal light chain mice |
JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
CN106995822B (zh) | 2011-09-19 | 2021-06-29 | 科马布有限公司 | 定制供人类使用的抗体、可变结构域和链 |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
US20130102031A1 (en) | 2011-10-25 | 2013-04-25 | Anaptysbio, Inc. | Use of somatic hypermutation to create insertion and deletion mutations in vitro |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
KR102186822B1 (ko) | 2011-12-20 | 2020-12-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
CA2863175A1 (en) | 2012-02-01 | 2013-08-08 | Regeneron Pharamaceuticals, Inc. | Humanized rodents that express heavy chains containing vl domains |
NZ628943A (en) | 2012-03-02 | 2016-08-26 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
RU2683514C2 (ru) | 2012-03-06 | 2019-03-28 | Регенерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
EP2825035A1 (en) | 2012-03-16 | 2015-01-21 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
RS62121B1 (sr) | 2012-06-12 | 2021-08-31 | Regeneron Pharma | Humanizovane nehumane životinje sa ograničenim lokusima imunoglobulinskog teškog lanca |
DK3327127T3 (da) | 2012-12-12 | 2021-06-28 | Broad Inst Inc | Fremføring, modificering og optimering af systemer, fremgangsmåder og sammensætninger til sekvensmanipulation og terapeutiske anvendelser |
BR112015019350A2 (pt) | 2013-02-20 | 2017-08-22 | Regeneron Pharma | Animal não humano, locus de imunoglobulina, e, métodos de fabricação de um animal não humano, para a obtenção de uma sequência de ácido nucleico e de fabricação de uma proteína de ligação ao antígeno |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US20150033372A1 (en) | 2013-05-01 | 2015-01-29 | Kymab Limited | Human VpreB & Chimaeric Surrogate Light Chains in Transgenic Non-Human Vertebrates |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US20140331339A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Limited | Transgenic Non-Human Assay Vertebrates, Assays and Kits |
US20140331344A1 (en) | 2013-05-03 | 2014-11-06 | Kymab Ltd. | Transgenic Animals |
NL2013554B1 (en) | 2013-10-01 | 2016-01-08 | Kymab Ltd | Animal models and therapeutic molecules. |
-
2012
- 2012-03-29 US US13/434,361 patent/US9253965B2/en active Active
- 2012-11-30 EP EP12795841.1A patent/EP2785845A2/en not_active Withdrawn
- 2012-11-30 WO PCT/GB2012/052960 patent/WO2013061098A2/en active Application Filing
-
2013
- 2013-03-18 CA CA2867530A patent/CA2867530A1/en not_active Abandoned
- 2013-03-18 IN IN1879MUN2014 patent/IN2014MN01879A/en unknown
- 2013-03-18 CN CN201380027944.1A patent/CN104334732B/zh active Active
- 2013-03-18 EP EP18153171.6A patent/EP3366126B1/en active Active
- 2013-03-18 DK DK13711119.1T patent/DK2831244T3/en active
- 2013-03-18 WO PCT/GB2013/050682 patent/WO2013144566A2/en active Application Filing
- 2013-03-18 JP JP2015502439A patent/JP6336435B2/ja active Active
- 2013-03-18 EP EP13711119.1A patent/EP2831244B1/en active Active
- 2013-03-18 AU AU2013239501A patent/AU2013239501B2/en not_active Expired - Fee Related
- 2013-03-18 NZ NZ629202A patent/NZ629202A/en not_active IP Right Cessation
- 2013-03-18 SG SG11201405058WA patent/SG11201405058WA/en unknown
-
2015
- 2015-02-06 HK HK15101357.8A patent/HK1200872A1/xx unknown
-
2016
- 2016-02-08 US US15/018,670 patent/US9924705B2/en active Active
- 2016-12-19 US US15/383,202 patent/US9938358B2/en active Active
- 2016-12-19 US US15/383,196 patent/US9938357B2/en active Active
-
2018
- 2018-04-09 US US15/948,709 patent/US10774155B2/en active Active
- 2018-05-02 JP JP2018088749A patent/JP2018119012A/ja active Pending
-
2020
- 2020-07-30 JP JP2020129123A patent/JP2020176140A/ja active Pending
- 2020-09-15 US US17/020,997 patent/US20210079118A1/en not_active Abandoned
-
2022
- 2022-09-19 US US17/947,884 patent/US20230159660A1/en active Pending
- 2022-11-04 JP JP2022177513A patent/JP7475415B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2014MN01879A (ko) | ||
WO2015049517A3 (en) | Animal models and therapeutic molecules | |
HK1162119A1 (en) | Animal models and therapeutic molecules | |
MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
NZ718280A (en) | Antibodies against claudin 18.2 useful in cancer diagnosis | |
EP2604110A3 (en) | Animal models and therapeutic molecules | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
MY178142A (en) | Anti-phf-tau antibodies and their uses | |
EA201790664A1 (ru) | Антитела против мезотелина и иммуноконъюгаты | |
EP4324480A3 (en) | Anti-transferrin receptor antibodies and methods of use | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
IN2014MN01642A (ko) | ||
EA201790175A1 (ru) | Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований | |
MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
MX353476B (es) | Anticuerpos anti-cxcl13 y metodos para usarlos. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX360368B (es) | Regiones de anticuerpo modificado y sus usos. | |
AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
MX2014004326A (es) | Anticuerpos a cd1d. | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
MX2016005854A (es) | Anticuerpo anti-her3 alosterico de la neuregulina. | |
MX2010000979A (es) | Metodos y composiciones para tratar enfermedad autoinmune. |